(90)Y-ibritumomab tiuxetan followed by reduced-intensity conditioning and allo-SCT in patients with advanced follicular lymphoma.
Reduced-intensity conditioning (RIC) hematopoietic SCT (HSCT) is a potentially curative therapeutic option for patients with advanced follicular lymphoma (FL), but disease relapse remains the most common cause of failure. Radioimmunoconjugates administered before RIC allo-HSCT may enhance cytoreduction and allow more time for GVL effect to develop without the associated toxicity of a myeloablative HSCT. We performed a retrospective study to describe the outcomes of patients with relapsed, refractory or transformed FL who received yttrium-90 ((90)Y)-ibritumomab tiuxetan followed by fludarabine and low-dose BU RIC allogeneic HSCT at the Dana-Farber Cancer Institute between 2006 and 2009, inclusively. Twelve patients were identified with a median age of 55 (40-66) years and a median number of lines of therapy of 5 (2-10). Two patients (17%) had transformed to a more aggressive histology and five (42%) had chemorefractory FL. Cumulative incidences of grade II-IV acute GVHD at 100 days were 17% (±11%) and chronic GVHD at 12 months were 63% (±19%). Two-year non-relapse mortality was 18% (±12%). Two-year OS and PFS were 83% (±11%) and 74% (±13%), respectively. This treatment is associated with favorable outcomes including acceptable rates of GVHD and relapse in advanced FL patients, and warrants prospective studies.
Lymphoma Program, Department of Medical Oncology, Harvard Medical School, Dana-Farber Cancer Institute, Boston, MA 02115-6084, USA.
K E
KE
Abou-Nassar
K E
KE
Stevenson
J H
JH
Antin
K
K
McDermott
V T
VT
Ho
C S
CS
Cutler
A S
AS
LaCasce
E D
ED
Jacobsen
D C
DC
Fisher
R J
RJ
Soiffer
E P
EP
Alyea
J
J
Koreth
A S
AS
Freedman
D000328:Adult; D000368:Aged; D000911:Antibodies, Monoclonal / Q000008:administration & dosage*; D002908:Chronic Disease; D018572:Disease-Free Survival; D005260:Female; D005500:Follow-Up Studies; D006086:Graft vs Host Disease / Q000209:etiology / Q000401:mortality / Q000473:pathology / Q000628:therapy; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D015994:Incidence; D008224:Lymphoma, Follicular / Q000401:mortality* / Q000473:pathology / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D012189:Retrospective Studies; D015996:Survival Rate; D019172:Transplantation Conditioning; D014184:Transplantation, Homologous
D000911:Antibodies, Monoclonal; C422802:ibritumomab tiuxetan
Biol Blood Marrow Transplant. 2008 Aug;14(8):920-6
18640576
Br J Haematol. 2009 Jun;145(6):816-24
19344418
J Clin Oncol. 2005 Oct 20;23(30):7565-73
16186600
J Clin Oncol. 2008 Jan 10;26(2):211-7
18056679
Blood. 2002 Dec 15;100(13):4310-6
12393626
Blood. 2001 Dec 15;98(13):3595-9
11739162
Bone Marrow Transplant. 2008 Feb;41(4):355-61
18026153
Biol Blood Marrow Transplant. 2009 Jul;15(7):844-50
19539216
Blood. 2002 Jun 15;99(12):4336-42
12036859
Blood. 2010 Sep 9;116(10):1795-802
20530284
Br J Cancer Suppl. 1975 Mar;2:386-401
1101927
Biol Blood Marrow Transplant. 2008 Apr;14(4):418-25
18342784
Blood. 2009 Dec 24;114(27):5444-53
19786617
Blood. 2004 Jun 15;103(12):4429-31
15016644
Leuk Lymphoma. 2006 Jan;47(1):59-63
16321828
J Clin Oncol. 2003 Nov 1;21(21):3918-27
14517188
Bone Marrow Transplant. 1995 Jun;15(6):825-8
7581076
Biol Blood Marrow Transplant. 2008 Feb;14(2):236-45
18215784
J Clin Oncol. 2008 Dec 10;26(35):5767-74
19001324
Exp Hematol. 2007 Apr;35(4):534-40
17379063
Clin Cancer Res. 2004 Dec 1;10(23):7792-8
15585610
Biol Blood Marrow Transplant. 2007 Sep;13(9):1057-65
17697968
Cancer Biother Radiopharm. 2007 Oct;22(5):684-91
17979571
J Clin Oncol. 2008 Nov 10;26(32):5156-64
18854568
Biol Blood Marrow Transplant. 2007 Aug;13(8):956-64
17640600
J Clin Oncol. 2002 Aug 1;20(15):3262-9
12149300
Cancer. 2007 May 1;109(9):1804-10
17380530
Hematology Am Soc Hematol Educ Program. 2006;:303-10
17124076
J Clin Oncol. 2005 Jan 20;23(3):461-7
15534357
Ann Oncol. 2006 Oct;17(10):1539-45
16940035